Newsroom

Media

Newsroom - 2022

Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance

21 DEC 2022 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Nicardipine Hydrochloride Capsules, 20 mg and 30 mg

19 DEC 2022 | READ MORE

Glenmark Pharmaceuticals reaches settlement agreement with Pfizer for Axitinib Tablets, 1 mg and 5 mg

22 NOV 2022 | READ MORE

Glenmark Pharma reports revenue growth of 7.2% YoY and EBITDA margin of 18.4% for Q2 FY 2022-23

11 NOV 2022 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Sodium Phenylbutyrate Tablets USP, 500 mg

02 NOV 2022 | READ MORE

Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

31 OCT 2022 | READ MORE

Glenmark becomes the First Company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination for Adults with Type 2 Diabetes having Comorbidities

20 OCT 2022 | READ MORE

Glenmark becomes the First Pharmaceutical Company to launch Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

06 OCT 2022 | READ MORE

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

23 SEP 2022 | READ MORE

Hikma launches RYALTRIS™ seasonal allergic rhinitis nasal spray in the US

30 AUG 2022 | READ MORE

Glenmark Pharma reports Revenue of INR 27,773 Mn and PAT of INR 2,111 Mn for Q1 FY 2022-23

10 AUG 2022 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Capsules and Ferrous Fumarate Capsules,1 mg/20 mcg

29 JULY 2022 | READ MORE

Glenmark Pharmaceuticals and SaNOtize Announce Peer Reviewed Publication of Its Phase 3 Clinical Trials on SaNOtize's Novel Nitric Oxide Nasal Spray for COVID-19 in Lancet Journal

13 JULY 2022 | READ MORE

Glenmark Pharmaceuticals launches MINYM® GEL – India’s First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

11 JULY 2022 | READ MORE

Glenmark launches Sitagliptin and its Fixed Dose Combinations, at Affordable Price for Adults with Type 2 Diabetes in India

07 JULY 2022 | READ MORE

Glenmark Pharmaceuticals Inc., USA continues to expand its Over-The-Counter (OTC) Portfolio with the acquisition of approved ANDAs from Wockhardt Limited

28 JUNE 2022 | READ MORE

Glenmark becomes the First Pharmaceutical Company to launch Indacaterol + Mometasone Fixed-Dose Combination Drug for Asthma in India

16 JUNE 2022 | READ MORE

Glenmark Pharma reports revenue growth of 5.6% YoY Q4; 12.4% for the full year FY 2021-22

27 MAY 2022 | READ MORE

Glenmark Pharmaceuticals receives sANDA approval for Abiraterone Acetate Tablets USP, 500 mg

20 MAY 2022 | READ MORE

Glenmark Pharmaceuticals receives tentative ANDA approval for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%

09 MAY 2022 | READ MORE

Glenmark receives the ‘India Pharma Innovation of the Year’ Award from the Government of India

27 APR 2022 | READ MORE

Glenmark becomes the first pharmaceutical company to launch Teneligliptin + Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India

25 APR 2022 | READ MORE

Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin's Lymphoma

11 APR 2022 | READ MORE

Glenmark receives ANDA approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg

21 MAR 2022 | READ MORE

Glenmark inks agreement with Astrazeneca to commercialize its product Pulmicort Respules® in Columbia

14 FEB 2022 | READ MORE

Glenmark Pharma reports revenue growth of 13.9% and EBITDA growth of 30.8% YoY for Q3 FY 2021-22

11 FEB 2022 | READ MORE

Glenmark launches Nitric Oxide Nasal Spray (FabiSpray®) in India for the Treatment of Adult Patients with COVID-19 in partnership with SaNOtize

09 FEB 2022 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Metronidazole Vaginal Gel, 0.75%

28 JAN 2022 | READ MORE

Glenmark Pharmaceuticals receives ANDA approval for Bisoprolol Fumarate and Hydrochlorothiazide Tablets USP, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg

27 JAN 2021 | READ MORE

Glenmark Specialty S.A. and Lotus International Pte. Ltd. enter into Exclusive Licensing Agreement for commercializing Ryaltris™ Nasal Spray in Singapore, Hong Kong and Vietnam

20 JAN 2022 | READ MORE

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0.4 mg/5 mL (0.08 mg/mL) Single-Dose Pre-Filled Syringe

17 JAN 2022 | READ MORE

Glenmark Specialty S.A. (Switzerland) receives NDA Approval by the United States Food and Drug Administration (FDA) for Ryaltris™ Nasal Spray for the Treatment of Symptoms of Seasonal Allergic Rhinitis in Adults and Pediatric Patients 12 Years of Age and Older

14 JAN 2022 | READ MORE